Evaluation of Circulating Tumor Cells and Serological Cell Death Biomarkers in Small Cell Lung Cancer Patients Undergoing Chemotherapy
- 31 August 2009
- journal article
- research article
- Published by Elsevier BV in The American Journal of Pathology
- Vol. 175 (2), 808-816
- https://doi.org/10.2353/ajpath.2009.090078
Abstract
No abstract availableKeywords
This publication has 38 references indexed in Scilit:
- Clinical Evaluation of M30 and M65 ELISA Cell Death Assays as Circulating Biomarkers in a Drug-Sensitive Tumor, Testicular CancerNeoplasia, 2008
- Circulating Tumor Cells Predict Survival Benefit from Treatment in Metastatic Castration-Resistant Prostate CancerClinical Cancer Research, 2008
- Relationship of Circulating Tumor Cells to Tumor Response, Progression-Free Survival, and Overall Survival in Patients With Metastatic Colorectal CancerJournal of Clinical Oncology, 2008
- Preclinical evaluation of M30 and M65 ELISAs as biomarkers of drug induced tumor cell death and antitumor activityMolecular Cancer Therapeutics, 2008
- Optimisation of circulating biomarkers of cell death for routine clinical useAnnals of Oncology, 2008
- Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to ChemotherapyClinical Cancer Research, 2007
- Small cell lung cancer and targeted therapiesCurrent Opinion in Oncology, 2007
- Variations of soluble fas and cytokeratin 18-Asp 396 neo-epitope in different cancers during chemotherapy.2006
- Method validation and preliminary qualification of pharmacodynamic biomarkers employed to evaluate the clinical efficacy of an antisense compound (AEG35156) targeted to the X-linked inhibitor of apoptosis protein XIAPBritish Journal of Cancer, 2006
- A Review of First-Line Treatment for Small-cell Lung CancerJournal of Thoracic Oncology, 2006